Follow us...


Search News Archives





View Channel

Laboratory Products



View Channel

Special Offers and Promotions


Microscopy | Image Analysis



View Channel

Separation Science



View Channel

Coronavirus (COVID-19)



View Channel

Research & Case Studies



View Channel

Conferences | Events

Oxford Gene Technology and Abcodia form Partnership

Oxford Gene TechnologyOxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has today announced a collaborative agreement with Abcodia, a specialist company engaged in the validation and discovery of biomarkers of cancer and other age-related diseases, aimed at improving the early detection of pancreatic cancer. As part of this collaboration, Abcodia will provide access to its large prospective serum biobank, to harness samples taken from individuals up to 7 years before the diagnosis of pancreatic cancer.  OGT will apply its functional protein array platform and its GenefficiencyTM microRNA profiling array to identify pancreatic cancer specific biomarkers that can be used as diagnostic indicators of developing pancreatic cancer. Both OGT and Abcodia will bring their expertise in experimental design and analysis.

At present, the prognosis for someone diagnosed with pancreatic cancer is poor. The limitations of current diagnostic techniques mean that often the cancer is not detected until after it has spread. The identification of sensitive and specific biomarkers that allow early detection of pancreatic cancer could therefore significantly increase survival rates.

Julie Barnes, Chief Executive Officer, Abcodia said: "We are very excited to be able to form this strategic partnership with OGT. The combination of the breadth of the OGT technology with our unique serum biobank provides a real opportunity to significantly advance the field of early pancreatic cancer diagnosis and screening."

John Anson, Vice President Biomarker Discovery, OGT commented: "A common challenge in discovering novel cancer biomarkers is the availability of well characterised samples for the disease area of interest. We are delighted that, through our partnership with Abcodia, we are able to employ our unique and integrated genomic and proteomic array technologies to identify sensitive and specific biomarkers for pancreatic cancer."

Financial details of the partnership were not disclosed.

For more information about OGT's cytogenetic, genomic and biomarker solutions visit

If you have not logged into the website then please enter your details below.


Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin


Request your free copies HERE




Popular this Month

Top 10 most popular articles this month


Today's Picks




Looking for a Supplier?

Search by company or by product


Company Name:






Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


Media Partners